A specific dietary amino acid ratio — 0.5% lysine combined with 0.5% arginine — reduces tumor burden and extends survival in tumor-bearing mice, while a seemingly reasonable alternative (0.25% lysine/1% arginine) paradoxically accelerates tumor progression. Single-cell RNA sequencing revealed that the harmful imbalanced formulation drives systemic immune remodeling: increased B cells and M1-annotated macrophages, reduced T cells, suppressed Rps6 and Rps29 ribosomal proteins, and elevated hemoglobin genes Hba-a1 and Hbb-bt — collectively implicating disrupted mTOR signaling and translational machinery in immune compartments. Validation used both Drosophila and mouse models across a defined therapeutic window.
The finding matters because most amino acid restriction strategies in oncology target single nutrients — arginine or methionine, for instance — without accounting for competitive dynamics between tumor and immune cells. This study reframes the problem as a ratio problem, not a deprivation problem. The practical implication is striking: getting the lysine-arginine balance wrong doesn't simply fail to help, it may actively harm. That biphasic dose-response curve demands caution before any clinical translation. Significant limitations apply: these are preclinical rodent and insect models only, no human data exist, and the immune dependency mechanism requires further dissection. Still, the scRNA-seq mechanistic depth elevates this beyond typical dietary oncology papers. For the longevity field, where mTOR modulation is central, the intersection of dietary amino acid ratios and immune-mTOR crosstalk is a genuinely underexplored and promising avenue.